Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“For years, BCMA-directed therapies have delivered remarkable results in heavily pretreated multiple myeloma. The question has been: what happens if we move them earlier?
The phase 3 MajesTEC-9 trial provides a compelling answer.
Patients with relapsed or refractory multiple myeloma who had received just 1–3 prior lines of therapy were randomized to receive either teclistamab, a BCMA×CD3 bispecific antibody, or standard regimens including PVd or Kd.
The results were striking.
At 18 months, nearly 70% of patients treated with teclistamab remained progression-free, compared with just 27% in the standard therapy arm. Complete response rates were nearly four times higher with teclistamab (66% vs 17%), and an overall survival advantage was already emerging despite relatively early follow-up.
Perhaps most notable is what these data suggest about the evolving treatment landscape.
Not long ago, bispecific antibodies were viewed primarily as options for patients who had exhausted conventional therapies. Today, teclistamab is demonstrating the potential to outperform established regimens much earlier in the disease course.
The tradeoff remains clear: deeper responses come with increased immune-related toxicities and a substantial burden of infections, highlighting the importance of vigilant supportive care.
Nevertheless, MajesTEC-9 represents another milestone in the shift of T-cell–redirecting therapies from the final chapters of myeloma treatment toward the front lines of relapse management.
The future of multiple myeloma may increasingly be defined not by chemotherapy combinations, but by harnessing a patient’s own immune system earlier and more effectively than ever before.”
Title: Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Authors: Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M. Ariës, Natalia A. Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, Ola Landgren.
Read the article here.
Other articles about MajesTEC-9 on OncoDaily.